Showing 9121-9130 of 10817 results for "".
- Actavis to Acquire Warner Chilcotthttps://practicaldermatology.com/news/20130521-actavis_to_acquire_warner_chilcott/2459533/Actavis will acquire Warner Chilcott plc in a stock-for-stock transaction valued at approximately $8.5 billion. If successfully completed, the transaction will create a global specialty pharmaceutical company with approximately $11 billion in combined annual revenue, and the third-largest US special
- Clark Pharmaceuticals, Ferndale Healthcare Launch DerMendhttps://practicaldermatology.com/news/20130521-clark_pharmaceuticals_ferndale_healthcare_launch_dermend/2459534/Clark Pharmaceuticals partnered with Ferndale Healthcare to launch DerMend Moisturizing Bruise Formula. The formula is predicated on the idea that skin over 50 tends to get thinner and bruises more easily. Blood thinners, even those like low-dose baby aspirin, can cause skin to bruise. DerMend is de
- AARS and AAP Release Acne Recommendationshttps://practicaldermatology.com/news/20130520-aars_and_aap_release_acne_recommendations/2459536/Evidence-based recommendations for the diagnosis and treatment of pediatric acne were recently published in Pediatrics. These recommendations were developed through the American Acne Rosacea Society (AARS) and endorsed by the American Academy of Pediatrics. The recommendations are a result of a two
- Georgia Governor Signs AMA Model Legislationhttps://practicaldermatology.com/news/20130520-georgia_governor_signs_ama_model_legislation/2459538/Georgia lawmakers enacted legal protections for physicians engaged in quality and delivery improvement initiatives included in the federal health care reform law. This first-of-its-kind legislation reinforces the concept that medical decisions are made based on a patient's unique medical needs. The
- L'Oreal Paris Partners with Melanoma Research Alliancehttps://practicaldermatology.com/news/20130520-loreal_paris_partners_with_melanoma_research_alliance/2459539/L'Oreal Paris formed an alliance with the Melanoma Research Alliance (MRA). Over the next three years, L'Oreal Paris will donate over $750,000 to the MRA to fund the new L'Oreal Paris-MRA Team Science Award, led by internationally renowned cancer researcher Dr. Meenhard Herlyn, to research ways to h
- Amgen to Present at ASCOhttps://practicaldermatology.com/news/20130516-amgen_to_present_at_asco/2459543/Amgen will present data from several studies of both pipeline and marketed products at the 2013 American Society of Clinical Oncology Annual Meeting from May 31 to June 4 in Chicago. Abstracts will include study results on talimogene laherparepvec,
- OXY Unveils Overhauled Acne Lineshttps://practicaldermatology.com/news/20130507-oxy_unveils_overhauled_acne_lines/2459550/After 30 years, the OXY brand (Mentholatum Company) has had a makeover and now offers two distinct lines grouped by active ingredients designed to either kill acne (benzoyl peroxide) or provide maintenance for acne-prone skin (salicylic acid). The OXY Maximum Action line includes, among others, OXY
- Pliaglis Launches in Europehttps://practicaldermatology.com/news/20130502-pliaglis_launches_in_europe/2459551/Nuvo Research Inc. and Galderma Pharma, S.A. launched Pliaglis (lidocaine and tetracaine) Cream 7%/7% in Europe. Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, and licenses have been issued in 14 of the 16 European cou
- AcneFree Products with Micro-Benzoyl Peroxide Now Availablehttps://practicaldermatology.com/news/20130430-acnefree_products_with_micro-benzoyl_peroxide_now_available/2459553/Formulated with Advanced Micro-Benzoyl Peroxide, new AcneFree Clear Skin Products from Valeant Consumer Products are formulated to effectively target acne with less irritation. Three kits are available: The AcneFree 24 Hour Acne Clearing System (AcneFree
- Ipsen's Dysport Approved for Use in Canadahttps://practicaldermatology.com/news/20130418-ipsens_dysport_approved_for_use_in_canada/2459560/Health Canada granted a marketing authorization for Dysport (Botulinum toxin type A for injection) for the temporary improvement in the appearance of moderate to severe frown lines (glabellar lines) in adult patients younger than 65 years of age. Medicis Aesthetics Canada, a division of Valeant Phar